Using Computer Tasks to Predict Response to Antidepressants
Primary Purpose
Depression
Status
Completed
Phase
Phase 1
Locations
United Kingdom
Study Type
Interventional
Intervention
General Practitioner Emotional Test Battery (GP-ETB)
Sponsored by

About this trial
This is an interventional treatment trial for Depression
Eligibility Criteria
Inclusion Criteria:
- Male or female and aged between 18 and 65 inclusive.
- Diagnosed by GP with a depressive episode requiring treatment with citalopram (new or recurrent diagnosis).
- Prescribed citalopram by GP for treatment of depression within past 3 days but has not yet started taking medication.
- Is intending to start citalopram treatment within 2 days of Visit 1.
- Fluent English speaker.
- Has not consumed more than 4 units of alcohol in the 24 hours prior to Visit 1 and has not consumed any alcohol in the 8 hours prior to Visit 1.
- Has not smoked tobacco in the 2 hours prior to completing the GP-ETB at Visit 1.
- Has not consumed any beverages containing caffeine for 2 hours prior to completing the GPETB at Visit 1.
- Has not consumed any psychoactive substances for 24 hours prior to Visit 1.
- Willing and able to comply with study procedures, including treatment with citalopram and study prohibitions and restrictions.
- Patient must have signed the informed consent form prior to the first study related procedure indicating they understand the purpose of and procedures required for the study and are willing to participate in the study.
Exclusion Criteria:
- Pregnant or breastfeeding, or planning to become pregnant during study, as determined through interview with patient.
- Currently taking antidepressant medication.
- Has taken antidepressant medication in the past 3 months.
- Currently taking anti-psychotic or regular sedative medication, or is likely to require these during the study.
- Regular (at least every week) use of recreational drugs including cannabis, as determined through interview with patient.
- History of alcohol or substance dependence within the last 12 months from Visit 1, as assessed using standard screening questions.
- Unlikely to be able to complete GP-ETB test.
- Requires immediate referral to secondary care mental health services.
- Is employed by the investigator or is related to the investigator
- Currently taking part in a drug study or another device study.
Sites / Locations
- Cornerstone Practice
- Knowle House Surgery
- Wareham Surgery
- Oak Street Medical Centre
- The Surgery
- Harbottle Surgery
- Rosedale Surgery
- Atherstone Surgery
- Sherbourne Medical Centre
- Bradford Road Medical Centre
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
All participants
Arm Description
Study has a single, non-interventional arm where the General Practitioner Emotional Test Battery (GP-ETB) will be administered.
Outcomes
Primary Outcome Measures
Change in Quick Inventory of Depressive Symptomology - Self Report (QIDS-SR) score from baseline (pre-dose of citalopram) to Day 28-42 post first dose of citalopram
The QIDS-SR is a self report questionnaire and will be completed at baseline pre first dose of citalopram and at day 28-42 post first dose of citalopram. Scores will be compared.
Change in General Practitioner P1vital Oxford Emotional Test Battery (GP-ETB) scores from baseline (pre first dose of citalopram) to Visit 2 (7-9 days post first dose of citalopram)
Patients will complete the GP-ETB tasks at baseline and 7-9 days post their first dose of citalopram and the scores compared.
Secondary Outcome Measures
Change in Montgomery-Asberg Depression rating Scale (MADRS) score from baseline (pre-dose of citalopram) to Day 28-42 post first dose of citalopram
The MADRS interview will be conducted at baseline and again at the end of the study (day 28-42 post first dose of citalopram) and the scores compared.
Acceptability questionnaire results
All participants will complete an acceptability questionnaire about ease of use of the medical device.This visit occurs between Day 28 and day 42 after the first dose of citalopram taken by the patient. The data will be subjective text fields and Yes/No answers.
Adverse Events (AEs), Adverse Device Effects (ADEs) and device deficiencies will be recorded at each visit in the participant Case Report Form (CRF)
Assessment of safety will be made through AE's, ADEs and device deficiencies recorded on the Case Report Form for the study first patient enrolled (June 2014) throughout the study until last patient last visit (January 2015). AEs or ADEs that have not resolved by the time a patient leaves the study will be followed up until resolution.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02800577
Brief Title
Using Computer Tasks to Predict Response to Antidepressants
Official Title
An Exploratory Investigation in Depressed Patients Initiating Treatment With Citalopram, to Determine the Sensitivity and Specificity of the P1vital® Oxford GP-Emotional Test Battery in Predicting Drug Response and Non-response
Study Type
Interventional
2. Study Status
Record Verification Date
June 2016
Overall Recruitment Status
Completed
Study Start Date
June 2014 (undefined)
Primary Completion Date
January 2015 (Actual)
Study Completion Date
March 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
P1vital Products Limited
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
In England over 800,000 patients each year are either newly diagnosed with depression or present with a new episode of depression in primary care. The majority of patients do not respond to the first drug prescribed and have to try several different antidepressants before an effective treatment is found. Antidepressants have a slow clinical onset of action, taking 4 to 6 weeks before changes in mood become apparent. No test exists to guide General Practitioners (GPs) as to whether their patient is responding to the prescribed successive treatments. This often results in delays of many months before patients return to good mental health. The GP-ETB is a set of computer-based emotional processing tasks. It was developed and optimised to be sensitive to early changes in emotional bias that are indicative of successful antidepressant treatment. The current investigation is an exploratory study using the GP-ETB.
It will test the predictive ability of the GP-ETB with regard to later subjective drug response and nonresponse. The study will recruit depressed patients from primary care settings. There are no study drugs prescribed as part of this clinical investigation. Eligible patients will have been prescribed citalopram by their GP prior to study entry. The decision to initiate treatment with citalopram will be independent of study participation. The duration of the study is 5 months. Each patient will be required to attend 3 visits and total duration of the study for the patient will be 46 weeks. During the visits patients will be asked to complete a variety of questionnaires and GP-ETB tasks on the computer. Sensitivity and specificity data collected during this study will be used to develop a computer algorithm intended to predict response at 46 weeks, based on GP-ETB data collected 1 week after initiation of antidepressant treatment.
Detailed Description
The study is an exploratory, single arm, multi-centre, clinical investigation of a medical device. The study consists of a recruitment period followed within 3 days by the first study visit. After a GP has decided to prescribe citalopram for depression, GP assesses patient for suitability for study and provides a brief explanation of study to potentially suitable patient. Patient signs pre-study consent form agreeing to being contacted by researcher from the same or another GP surgery and agreeing not to take their first dose of citalopram until after their first study visit.
Recruitment and pre-screening Main study Patient Information Sheet/Informed Consent Form (PIS/ICF) will be provided. Researcher will contact patient and book the Visit 1 within 3 days from GP visit.
At Visit 1, patients will be screened and eligible patients will be enrolled in the study. Visit 1 procedures include:
Informed Consent
Demographics
Review of other medication
Brief medical history including depression history (if applicable)
Entry criteria check and enrolment into study
Quick Inventory of Depressive Symptomatology Self Report (QIDS-SR)
Montgomery-Åsberg Depression Rating Scale (MADRS)
Beck Depression Inventory®II (BDI-II)
GP-ETB (set of computer tasks)
Review of Adverse Events (AEs) and Adverse Device Effects (ADEs) and device deficiencies Patients will return approximately 1 week later for Visit 2 and will complete a variety of questionnaires and assessments:
QIDS-SR
BDI-II
GP-ETB
Assessment of compliance with study prohibitions and restrictions
Changes to antidepressant medication since last visit (e.g. increased dose, change of drug)
Concordance with prescribed antidepressant medication, as determined through interview with patient
Review of other medication
Review of AEs, ADEs and device deficiencies Visit 3 will be scheduled to take place 46 weeks after the first dose of citalopram. The following questionnaires and assessments will be completed:
QIDS-SR
MADRS
BDI-II
Acceptability questionnaire(s) relating to use of GP-ETB (patient and researcher)
Assessment of compliance with study prohibitions and restrictions
Changes to antidepressant medication since last visit (e.g. increased dose, change of drug)
Concordance with prescribed antidepressant medication, as determined through interview with patient
Review of other medication
Review of AEs, ADEs and device deficiencies At the end of the visit, patients will be considered to have completed the study.
Emotional Test Battery (GP-ETB) tasks: The GP-ETB is a series of computerised tasks during which participants must respond by button press to pictures (e.g. pictures of faces) or words presented on the screen. Some of the pictures are mildly emotional (e.g. a fearful face). Response bias for each Participant choice and reaction times are measured during the following tasks: Emotional Categorisation Task (ECAT) Number of words categorised as liked and disliked
% accuracy for each condition, Reaction time for each condition Emotional Recall Task (EREC) Total number of words recalled for each valence (positive, negative) Number of commission errors
Facial Expression Recognition Task (FERT):
accuracy of recognition of each emotion (happiness, fear, anger, disgust, surprise, sadness, neutral)
mis-classifications for each emotion Individual average reaction time for correct answers in each emotion Reaction time for all emotions Target sensitivity for each emotion Response bias for each emotion Questionnaires and rating scales: The questionnaires and rating scales used in the current study, except the acceptability questionnaires relating to use of GP-ETB (patient and researcher), are all validated and commonly used in experimental medicine studies.
The acceptability questionnaires relating to use of GP-ETB were created specifically for this study to obtain a data set for analysis of GP-ETB user satisfaction.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
80 (Actual)
8. Arms, Groups, and Interventions
Arm Title
All participants
Arm Type
Other
Arm Description
Study has a single, non-interventional arm where the General Practitioner Emotional Test Battery (GP-ETB) will be administered.
Intervention Type
Device
Intervention Name(s)
General Practitioner Emotional Test Battery (GP-ETB)
Intervention Description
The GP-ETB (Class I Medical Device) comprises three computer tasks. In the first task, the 'Emotional Categorisation Task' patients are given forty words that might be used to describe them and indicate whether they would 'like' or 'dislike' to be described by a particular word. In the 'Facial Expression Recognition Task' patients are asked to judge whether a briefly displayed face is expressing one of six emotions. In the final task, the 'Emotional Recall Task', the patient should recall as many words as they can from the series of words that were presented in the first task. The patients perform these tasks once before antidepressant treatment and again seven days after treatment begins.
Primary Outcome Measure Information:
Title
Change in Quick Inventory of Depressive Symptomology - Self Report (QIDS-SR) score from baseline (pre-dose of citalopram) to Day 28-42 post first dose of citalopram
Description
The QIDS-SR is a self report questionnaire and will be completed at baseline pre first dose of citalopram and at day 28-42 post first dose of citalopram. Scores will be compared.
Time Frame
Baseline (pre first dose of citalopram) to day 28-42 post first dose of citalopram)
Title
Change in General Practitioner P1vital Oxford Emotional Test Battery (GP-ETB) scores from baseline (pre first dose of citalopram) to Visit 2 (7-9 days post first dose of citalopram)
Description
Patients will complete the GP-ETB tasks at baseline and 7-9 days post their first dose of citalopram and the scores compared.
Time Frame
Baseline (pre first dose of citalopram) to day 7-9 post first dose of citalopram)
Secondary Outcome Measure Information:
Title
Change in Montgomery-Asberg Depression rating Scale (MADRS) score from baseline (pre-dose of citalopram) to Day 28-42 post first dose of citalopram
Description
The MADRS interview will be conducted at baseline and again at the end of the study (day 28-42 post first dose of citalopram) and the scores compared.
Time Frame
Baseline (pre first dose of citalopram) to day 28-42 post first dose of citalopram)
Title
Acceptability questionnaire results
Description
All participants will complete an acceptability questionnaire about ease of use of the medical device.This visit occurs between Day 28 and day 42 after the first dose of citalopram taken by the patient. The data will be subjective text fields and Yes/No answers.
Time Frame
The questionnaire will be completed at Day 28-42 post first dose of citalopram and will measure the participant's experience of the GP-ETB tests performed during the study
Title
Adverse Events (AEs), Adverse Device Effects (ADEs) and device deficiencies will be recorded at each visit in the participant Case Report Form (CRF)
Description
Assessment of safety will be made through AE's, ADEs and device deficiencies recorded on the Case Report Form for the study first patient enrolled (June 2014) throughout the study until last patient last visit (January 2015). AEs or ADEs that have not resolved by the time a patient leaves the study will be followed up until resolution.
Time Frame
AEs will be collected per patient from the baseline visit (day 0), from the time the consent form is signed, until study end (28-42 days post first dose of citalopram) or patient withdrawal.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female and aged between 18 and 65 inclusive.
Diagnosed by GP with a depressive episode requiring treatment with citalopram (new or recurrent diagnosis).
Prescribed citalopram by GP for treatment of depression within past 3 days but has not yet started taking medication.
Is intending to start citalopram treatment within 2 days of Visit 1.
Fluent English speaker.
Has not consumed more than 4 units of alcohol in the 24 hours prior to Visit 1 and has not consumed any alcohol in the 8 hours prior to Visit 1.
Has not smoked tobacco in the 2 hours prior to completing the GP-ETB at Visit 1.
Has not consumed any beverages containing caffeine for 2 hours prior to completing the GPETB at Visit 1.
Has not consumed any psychoactive substances for 24 hours prior to Visit 1.
Willing and able to comply with study procedures, including treatment with citalopram and study prohibitions and restrictions.
Patient must have signed the informed consent form prior to the first study related procedure indicating they understand the purpose of and procedures required for the study and are willing to participate in the study.
Exclusion Criteria:
Pregnant or breastfeeding, or planning to become pregnant during study, as determined through interview with patient.
Currently taking antidepressant medication.
Has taken antidepressant medication in the past 3 months.
Currently taking anti-psychotic or regular sedative medication, or is likely to require these during the study.
Regular (at least every week) use of recreational drugs including cannabis, as determined through interview with patient.
History of alcohol or substance dependence within the last 12 months from Visit 1, as assessed using standard screening questions.
Unlikely to be able to complete GP-ETB test.
Requires immediate referral to secondary care mental health services.
Is employed by the investigator or is related to the investigator
Currently taking part in a drug study or another device study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mike Browning, MRCPsych
Organizational Affiliation
P1vital Limited
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cornerstone Practice
City
March
State/Province
Cambridgeshire
ZIP/Postal Code
PE15 9BF
Country
United Kingdom
Facility Name
Knowle House Surgery
City
Plymouth
State/Province
Devon
ZIP/Postal Code
PL5 3JB
Country
United Kingdom
Facility Name
Wareham Surgery
City
Wareham
State/Province
Dorset
ZIP/Postal Code
BH20 4PG
Country
United Kingdom
Facility Name
Oak Street Medical Centre
City
Norwich
State/Province
Norfolk
ZIP/Postal Code
NR3 3DL
Country
United Kingdom
Facility Name
The Surgery
City
Burnhope
State/Province
Northumberland
ZIP/Postal Code
DH7 0BD
Country
United Kingdom
Facility Name
Harbottle Surgery
City
Morpeth
State/Province
Northumberland
ZIP/Postal Code
NE65 7DG
Country
United Kingdom
Facility Name
Rosedale Surgery
City
Carlton Colville
State/Province
Suffolk
ZIP/Postal Code
NR33 8LG
Country
United Kingdom
Facility Name
Atherstone Surgery
City
Atherstone
State/Province
Warwickshire
ZIP/Postal Code
CV9 1EU
Country
United Kingdom
Facility Name
Sherbourne Medical Centre
City
Leamington Spa
State/Province
Warwickshire
ZIP/Postal Code
CV32 4RA
Country
United Kingdom
Facility Name
Bradford Road Medical Centre
City
Trowbridge
State/Province
Wiltshire
ZIP/Postal Code
BA14 9AR
Country
United Kingdom
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Using Computer Tasks to Predict Response to Antidepressants
We'll reach out to this number within 24 hrs